Analysis of Beyfortus® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention

• 2024

  Log in to bookmark this resource.

  Log in
• Hélène Banoun
PMID: 39329969DOI: https://dx.doi.org/10.3390/cimb46090617

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This review article analyzes the Beyfortus® (Nirsevimab) Immunization Campaign's effectiveness in preventing RSV infections. Nirsevimab shows promise in reducing hospitalizations due to RSV with its strong binding to RSV F protein and extended lifespan. However, there are concerns about potential biases in studies and risks of antibody-dependent enhancement (ADE) leading to worsened infections. The incomplete assessment of ADE risk and the high cost of nirsevimab raise questions about the cost-effectiveness of mass immunization campaigns. The article highlights the need for further exploration of nirsevimab's effector functions and pharmacokinetics to ensure its safety and efficacy in preventing respiratory infections.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antibodies, Monoclonal; Bronchiolitis; Cost-Benefit Analysis; Hospitalization; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Immunization Programs; Antibody-Dependent Enhancement; Risk Assessment; Respiratory Syncytial Virus Vaccines

---

More like this

Ethical Obligations Regarding Short-Term Global Health Clinical Experiences: An American College of Physicians Position Paper 2018 · Johns Hopkins University, National Center for Ethics in Health Care, U.S. Department of Veterans Affairs, University of California –San Diego School of Medicine, University of California, San Diego, Virginia Mason Medical Center Chemical-Biological Terrorism and Its Impact on Children [2020] 2020 · Harvard Medical School, Boston Children's Hospital, Yale University, Children's Hospital Colorado, University of Colorado, American Academy of Pediatrics (AAP) What’s Old Is New Again: Measles 2025 · Ann and Robert H. Lurie Children’s Hospital, Baylor College of Medicine, Vanderbilt University, Norton Children's Hospital, University of Louisville, Children's Hospital Colorado

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---